Epithelial ovarian cancer is a disease in which malignant cells develop in the tissue that covers the ovary. Epithelial ovarian cancer is common in women who have a close relation such as mother, daughter, or sister diagnosed with the disease. In case of women having two or more blood relatives with ovarian cancer, the risk of developing the disease is higher. The hereditary information is carried from one generation to another through carrier genes received from parents. It has been estimated that hereditary ovarian cancer is approximately 5% - 10% more prevalent when compared to other cases of ovarian cancer.

Symptoms of epithelial ovarian cancer include pain in the pelvis area, swelling in the abdomen, and gastrointestinal problems such as bloating, etc. Diagnosis of epithelial ovarian cancer is conducted through a series of procedures such as pelvic examination, ultrasound, CA 125 assay, barium enema, intravenous pyelogram (IVP), CT scan, and biopsy.

Epithelial ovarian cancer starts from the surface layer of the ovary. It has been estimated by the Cancer Research UK that 90% of the diagnosed ovary cancers are of this type. The epithelial ovarian cancer market can be classified on the basis of types of epithelial ovarian cancer, diagnostic techniques, and treatment methods. On the basis of type, the epithelial ovarian cancer market can be segmented into five categories: stage I, stage II, stage III, and stage IV. According to the Cancer Research UK, serous epithelial ovarian cancer accounts for two-third of the epithelial ovarian cancer diagnosed every year, while 10% of the epithelial ovarian cancer diagnosed are of undifferentiated type. Different types of treatments are available for patients suffering from epithelial ovarian cancer such as surgery, radiation therapy, chemotherapy, immunotherapy, and targeted therapy.

In surgery, the uterus, cervix, fallopian tubes, ovaries, and omentum are removed from the body which may include. Post-surgery, patients are treated with radiation therapy and chemotherapy in order to kill the remaining tumor cells. Primary drugs used for the chemotherapy of epithelial ovarian cancer patients include BEP, carboplatin-taxon, gemcitabine-cisplatin, and VeIP. In addition to these, two other therapies for the treatment of epithelial ovarian cancer are under clinical trials such as biologic therapy and targeted therapy. Biologic therapy uses the patient’s immune system to fight against cancer, while targeted therapy involves the usage of drugs that identify and kill cancer-affected cells without causing any harm to the normal cells. Bevacizumab and PARP inhibitors are two such drugs under clinical trials for targeted therapy. Other major drugs under clinical trials include trebananib, paclitaxel, CVac, cositecan, and trabectadin.

According to the National Cancer Institute, in U.S., 22,240 new cases were diagnosed with ovarian cancer and the disease was responsible for 14,030 deaths. Such high rate of incidence and mortality is driving the epithelial ovarian cancer market. Asia Pacific represents the highest opportunity for epithelial ovarian cancer market owing to the increase in number of epithelial ovarian cancer and rise in awareness about the disease. Statistics released by the Cancer Australia revealed that in 2010, there were 1,305 new cases of ovarian cancer in Australia and around 1,470 and 1,640 new cases of ovarian cancer were predicted to be diagnosed in 2014 and 2020, respectively.

Increase in incidences of ovarian cancer, rise in research and development in drugs, favorable reimbursement provisions in developed and developing economies, development in healthcare infrastructure, and surge in government initiatives to promote research and awareness about the disease are projected to drive the epithelial ovarian cancer market during the forecast period. However, the high cost of treatment, stringent regulation in drug testing, and lack of skilled professionals for early diagnosis of disease are anticipated to hinder the growth of the market.

The global epithelial ovarian cancer market can be divided into five geographical region: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America leads the epithelial ovarian cancer market, followed by Europe, due to high prevalence of the disease and extensive research and development activities. Increase in incidences of ovarian cancer is expected to drive the global epithelial ovarian cancer market in Asia Pacific during the forecast period. Latin America and Middle East & Africa region are also anticipated to provide lucrative opportunities to the epithelial ovarian cancer market in the next few years. It can be largely ascribed to the growing biopharmaceutical industry in the region and the rise in participation of private players for expanding their geographical presence.

Major players in the epithelial ovarian cancer market include Boehringer Ingelheim GmbH, Millennium Pharmaceuticals, Inc., Amgen, Inc., ImmunoGen, Inc., Pharmacyclics, Inc., Bayer AG, Synta Pharmaceuticals Corp., Prima BioMed, Ltd., Oasmia Pharmaceutical AB, and Glycotope GmbH.

This intelligence report by TMR is the outcome of intense study and rigorous assessment of various dynamics shaping the growth of the market. TMR nurtures a close-knit team of analysts, strategists, and industry experts who offer clients tools, methodologies, and frameworks to make smarter decisions. Our objective, insights, and actionable analytics provide CXOs and executives to advance their mission-critical priorities with confidence.

The scrutiny of the various forces impacting the dynamics of the market, and key and associated industries, guides enterprises in understanding various consumer propositions. Our clients leverage these insights and perspectives to enhance customer experience in the fast-paced business environment.

All our insights and perspectives are broadly based on 4 Pillars or Stages: ASBC-S, which offer an elaborate and customizable framework for the success of an organization. The essence and the roles of these in organizational successes are highlighted below:

  • Agenda for CXOs: TMR, through the study, sets the tone for agendas that are pertinent to CEOs, CFOs, CIOs, and other CXO executives of businesses operating in the market. The perspectives help our clients to bridge the gap between agenda and action plan. TMR strives to offer guidance to CXOs to undertake mission-critical activities empowered by various business analysis tools, and boost the performance of the organizations. The perspectives guide you to decide on your own marketing mix that align well with the policies, visions, and mission.
  • Strategic Frameworks: The study offers how organizations are setting both short-term and long-term strategic plans. Our team of experts collaborate and communicate with you to understand these to make your organizations sustainable and resilient during tough times. The insights help them decide sustainable competitive advantage for each business units.
  • Benchmarking for Deciding Target Markets and Brand Positioning: The assessments in the study provides a scrutiny of marketing channels and marketing mix. Our various teams work synergistically with you to help identify your actual and potential direct, indirect, and budget competition areas. Additionally, the study helps you decide most effective budgets for various processes and promotional activities. Furthermore, the study guides you to set benchmarks for integrating people and processes with the 4Ps of marketing. Eventually, this will empower you to find out unique propositioning strategies and niches.
  • Business Composability for Sustainability (C-S): Constant strategy planning for sustainability characterizing our C-S framework in the report has become more relevant than before in the face of disruptions caused by pandemics, recessions, boom and bust cycles, and changing geopolitical scenario. The TMR study offers a high level of customization to help you achieve business composability. Composable enterprises are increasingly gaining the attention of CXOs in order to help them combat market volatility. Our analysts and industry experts help you wade through such uncertainties and guide you to become a smart sustainable business in entirety.

The study presents scrutiny of region-specific consumer and technology trends, including the most recent industry dynamics. These broadly cover but not limited to

  • North America, South America, and the Americas
  • Asia Pacific and Japan
  • Europe
  • Latin America
  • Middle East and Africa

The study offers data-driven insights and guidance of several aspects. Some of the more notable questions are:

  • What are the major recent trends that can influence the product life cycle and the RoI?
  • Which regulatory trends shape corporate-level, business-level, and functional-level strategies?
  • Which micromarketing initiatives of leading players will bring in investments?
  • What can be the best framework and tools for PESTLE analysis?
  • Which regions will witness rise in new opportunities?
  • Which are the game-changing technologies being used to capture new revenue streams in the near future?
  • Which operational and tactical frameworks are being adopted by various players in gaining customer loyalty?
  • What is the current and expected intensity of competition the market in the near future?

Disclaimer: This market research study is an ongoing effort and extreme care has been taken to maintain the highest levels of accuracy at all stages. However, in the light of the rapidly evolving business dynamics, some region-specific or other segment-specific changes may take time to be part of the study.

Enquiry Before Buying

TMR offers Enquiry Before Buying that help clients to get information on their business scenario required where syndicated solutions are not enough.

Enquiry Before Buying

Epithelial Ovarian Cancer Market